Merck is acquiring $1 billion in Seattle Genetics shares as part of a wide-ranging collaboration agreement.
News & Analysis: Seattle Genetics
SGEN earnings call for the period ending June 30, 2020.
Two drug approvals in just a few months gave investors reason to cheer.
These companies have products, products, and more products to keep revenue flowing.
SGEN earnings call for the period ending March 31, 2020.
With two new drugs on the market, revenue prospects look bright.
Tumultuous market conditions discounted the stock prices of these leading biotech companies.
Researchers didn't notice a heightened risk among people who consumed soy milk.
With a new drug on the market and another being reviewed by the FDA, Seattle Genetics’ revenue potential is climbing.
Patients with HER2-positive breast cancer could have a new treatment option from Seattle Genetics this summer.